CRISPR Therapeutics AG (NASDAQ: CRSP) is one of the best emerging technology stocks to buy right now. On September 3, Bank of ...

CRISPR Therapeutics AG is a long-term buy despite slow Casgevy uptake. Click for my updated look at CRSP earnings and the ...

CRISPR Therapeutics (NASDAQ:CRSP) traded higher in the premarket on Thursday after J.P. Morgan initiated its coverage with an Overweight recommendation, noting how the company stands out in the gene ...

CRISPR Therapeutics (CRSP) has been making waves lately, especially after announcing promising early clinical data for its ...

Fintel reports that on September 18, 2025, JP Morgan initiated coverage of CRISPR Therapeutics (NasdaqGM:CRSP) with a ...

The accepted abstract titles are available online on the AHA website. The data in the abstracts and presentations are ...

Researchers unveiled a genetic editing method that uses small nuclear RNAs instead of CRISPR. This approach produced fewer ...

CRISPR Therapeutics is the first company to secure an FDA approval of a gene-editing drug. That drug's underlying science, however, could be used to create treatments for any number of genetically ...

CAMBRIDGE, Mass. and SAN FRANCISCO, Sept. 17, 2025 /PRNewswire/ -- The laboratories of Dr. Kevin Bender and Dr. Nadav Ahituv ...

Shares of CRISPR Therapeutics AG (NASDAQ:CRSP – Get Free Report) hit a new 52-week high on Friday after an insider bought additional shares in the company. The company traded as high as $66.49 and ...